Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Cancer Control. 2020 Jan-Dec;27(1):1073274820911058. doi: 10.1177/1073274820911058.
Many aspects of cancer can be explained utilizing well-defined ecological principles. Applying these principles to cancer, cancer cells are an invasive species to a healthy organ ecosystem. In their capacity as ecosystem engineers, cancer cells release cytokines that recruit monocytes to the tumor and polarize them to M2-like protumor macrophages. Macrophages, recruited by the cancer cells, act as a secondary invasive species. The ecosystem engineering functions of M2-macrophages in turn support and stimulate cancer cell survival and proliferation. The cooperative ecosystem engineering of both the primary invasive species of the cancer cell and the secondary invasive species of the M2-macrophage thus creates a vicious cycle of tumor promotion. Targeting a specific aspect of this tumor-promoting ecosystem engineering, such as blocking efferocytosis by M2-like macrophages, may improve the response to standard-of-care anticancer therapies. This strategy has the potential to redirect cooperative protumor ecosystem engineering toward an antitumor ecosystem engineering strategy.
许多癌症方面都可以用明确的生态原则来解释。将这些原则应用于癌症,可以将癌细胞视为健康器官生态系统中的入侵物种。作为生态系统工程师,癌细胞会释放细胞因子,招募单核细胞进入肿瘤,并将其极化为 M2 样促肿瘤巨噬细胞。癌细胞招募的巨噬细胞充当次要入侵物种。M2 巨噬细胞的生态系统工程功能反过来又支持和刺激癌细胞的存活和增殖。因此,癌细胞这一主要入侵物种和 M2 巨噬细胞这一次要入侵物种的协同生态系统工程,形成了肿瘤促进的恶性循环。针对这种促进肿瘤的生态系统工程的特定方面,例如阻断 M2 样巨噬细胞的细胞凋亡吞噬作用,可能会提高对标准抗癌疗法的反应。这种策略有可能将协同的促肿瘤生态系统工程重新定向为抗肿瘤的生态系统工程策略。